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Background: Several studies have suggested a relationship between hepatitis B virus (HBV) basal core promoter/
pre-core mutations and HBV-induced acute-on-chronic liver failure (ACLF). Therefore, we evaluated this potential
relationship using a meta-analysis.
Methods: Chinese or English studies from 1966 to January 31, 2014 were included in the analysis. A random or
fixed-effects model was used to merge the odds ratios (ORs).
Results: We identified 31 case–control studies containing a total population of 1995 ACLF and 3822 chronic hepatitis B
(CHB) patients. Several mutations were significantly correlated with ACLF: T1753V (1.889, 95 % confidence interval (CI)
[1.357–2.631]), A1762T (2.696 [2.265–3.207]), G1764A (3.005 [2.077–4.347]), A1762T/G1764A (2.379 [1.519–3.727]), C1766T
(1.849 [1.403–2.437]), T1768A (2.440 [1.405–3.494]), A1846T (3.163 [2.157–4.639]), G1896A (2.181 [1.800–2.642]), G1899A
(3.569 [2.906–4.385]) and G1896A/A1762T/G1764A (1.575 [1.172–2.116]). Additionally, HBeAg-negative status
was also statistically significant for the progression to ACLF (OR = 2.813, 95 % CI = 2.240–3.533, p < 0.001). However, there
was no association between ACLF development and HBV genotype.
Conclusions: The HBV basal core promoter/pre-core mutations T1753V, A1762T, G1764A, C1766T, T1768A, A1846T,
G1896A and G1899A, and an HBeAg-negative status correlate with an increased risk of HBV-ACLF.
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Acute-on-chronic liver failure (ACLF) occurs when liver
function is suddenly compromised as a result of an inci-
dent [1]. In 2009, the Asia-Pacific Association for the
Study of the Liver (APASL) recommended the following
definition for ACLF: acute hepatic damage showing co-
agulopathy and jaundice, with encephalopathy and/or
ascites within 4 weeks, whether or not the patient had
been diagnosed with a chronic liver disease [2]. The ma-
jority of Chinese ACLF patients showed HBV-induced
hepatitis [3, 4]. Although the biological pathways that
mediate HBV infection and cause liver failure remain
unknown, studies suggest that mutations in the HBV* Correspondence: shengji.fang@163.com
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creativecommons.org/publicdomain/zero/1.0/viral genome may play a role in the progression of liver
diseases [5–8]. HBV mutations in the basal core pro-
moter (BCP)/pre-core (PC) regions are relatively well
understood [9–11]. BCP mutations lead to enhanced
HBV replication in vitro, while PC mutations break the
immune tolerance of chronic HBV infection by inhibit-
ing hepatitis B e antigen (HBeAg) translation [9–11].
Therefore, it is important to better understand the rela-
tionship between HBV mutations and ACLF, which may
have clinical utility. Several studies have shown that
HBV mutations in the BCP or PC regions are related to
the risk of ACLF, although the sample size and the mu-
tational sites tested were limited. Therefore, we per-
formed a meta-analysis to quantitatively evaluate data
from several available studies and investigated the rela-
tionship between HBV BCP/PC variations and the risk
of developing ACLF.distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Search results
We identified 2790, 831, 25 and 15 articles from the
PubMed, EMbase, Biomed Central and ClinicalTrials data-
bases, respectively. The four primary Chinese databases
used were: Chinese Biological Medicine, WANFANG
DATA, VIP and China National Knowledge Infrastructure,
which yielded 889, 1564, 1011 and 1303 studies, respect-
ively. This approach resulted in 3478 and 2203 studies after
removing duplicates from English and Chinese databases,
respectively. After title screening (4908 not relevant to
HBV mutation or liver failure, 310 associated with human
immunodeficiency virus (HIV) or hepatitis C virus), 463 po-
tential articles remained, which were reduced to 61 after
reviewing abstracts (338 were not related to mutations, 35
not related to ACLF and 29 related to hepatocellular carcin-
oma [HCC]). In addition, 30 articles were removed after
completing a full text scan (17 lacked control groups, 5 par-
ticipants were co-infected with other hepatic viruses, 2
were co-infected with HIV and 6 had HCC). We included
31 articles in our meta-analysis (Fig. 1).
Characteristics of trials included in this meta-analysis
The 31 trials were all case–control trials from China.
The primary mutation detection method was nested
polymerase chain reaction and sequencing. The quality
of the studies on the Newcastle-Ottawa Scale (NOS)
scale was between 5 and 7 (see Additional file 1: Table
S1). There were 5817 HBV patients, 1995 of whom had
ACLF. The most common mutations in the BCP/PC re-
gions that were associated with ACLF progression were
T1753V, A1762T/G1764A, A1762T, G1764A, C1766T,
T1768A, A1846T, G1862T, G1896A, G1899A and
G1896A/A1762T/G1764A (Table 1).
Patient characteristics
The studies that were included in this meta-analysis com-
pared patients with ACLF and patients with CHB of differ-
ent severities (mild, moderate and severe), or CHB patients
without differentiating by severity. There were mostly males
in both the ACLF and CHB groups, and the main geno-
types were B and C. There were significantly fewer ACLF
HBeAg-positive patients than HBeAg-negative patients,
while the opposite was seen in the CHB group (Table 2).
Data synthesis
Overall risk estimates
The risk assessment for ACLF patients with the muta-
tions of interest in the individual trials is summarized in
Additional file 2: Table S2 and Fig. 2. Overall, the follow-
ing mutations were found to be meaningfully related to
ACLF risk (shown as summary OR and 95 % [CI]):
T1753V (1.919 [1.414–2.606]), A1762T (2.685 [2.264–
3.185]), G1764A (2.901 [2.041–4.122]), A1762T/G1764Adouble mutation (2.376 [1.548–3.648]), C1766T (1.849
[1.403–2.437]), T1768A (2.199 [1.563–3.094]), A1846T
(3.163 [2.157–4.639]), G1896A (2.181 [1.800–2.642]),
G1899A (3.525 [2.882–4.312]) and G1896A/A1762T/
G1764A triple mutation (1.575 [1.172–2.116]). G1862T
was not significantly associated with ACLF risk, but when
we removed the study conducted by Xiaoqiang Ren, statis-
tical significance was achieved (summary OR= 2.579
[1.510–4.405], p = 0.001).
Subgroup analysis
We evaluated two subgroups, one matched by only pa-
tient age and sex, and the other matched by HBV geno-
type and DNA load, age and sex. The summary OR of
ACLF risk for several variations was lower in matched
subgroups than that in unmatched subgroups, such as
T1753V, A1762T, G1764A, C1766T, G1896A, G1899A
and A1846T, while an opposite result was observed for
A1762T/G1764A and T1768A (Table 3).
Prediction of ACLF by HBV mutation
We evaluated mutation frequency as a possible biomarker
to predict ACLF. Most of the mutation sites showed low
sensitivity and relatively high specificity, except A1762T,
which had a sensitivity of 74.5 % (95 % CI = 71.9–76.9 %)
and specificity of 45.8 % (95 % CI = 43.7–47.9 %). G1764A
showed a high positive prediction value (PPV; 80.1 %, 95 %
CI, 77.7–82.4; Table 4).
HBV genotype and HBeAg status
The summary OR of HBeAg-negative was 2.813 (95 % CI
[2.240–3.533], p < 0.001). However, there was no evidence
indicating that the HBV genotype B was significantly re-
lated to ACLF (Fig. 3), although we found that this result
was unstable using a sensitivity analysis of the following
studies: Aiming Zhang, Xiaodong Li, Zhengang Zhao,
Xiaoyan Ma, Mingxian Zhou and Tao Yan. When these
studies were removed, the summary OR p value was less
than 0.05, indicating that more studies were needed to de-
termine the relationship between HBV genotypes and
ACLF development.
Assessment of within-group heterogeneity, publication
bias and sensitivity analysis
There was a large amount of heterogeneity between differ-
ent trials for T1753V, G1764A, A1846T, G1862T, G1896A
and A1762T/G1764A. We therefore conducted a sensitivity
analysis using a “leave one out” approach and Egger’s test-
ing, and found that these mutations were not influential,
except for G1862T. Except for those with G1764A and
G1896A/A1762T/G1764A, we did not observe any publica-
tion bias with T1753V, A1762T, A1762T/G1764A, C1766T,
T1768A, A1846T, G1862T, G1896A or G1899A, (Table 5
and Fig. 4).
Fig. 1 Flow chart of article selection
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Our meta-analysis showed that T1753V, A1762T, G1764A,
A1762T/G1764A, C1766T, T1768A, A1846T, G1896A,
G1899A and G1896A/A1762T/G1764A were all related to
increasing the risk of HBV-ACLF by a factor of 1.919,
2.685, 2.901, 2.376, 1.849, 2.199, 3.163, 2.181, 3.525 and
1.575, respectively.To further confirm these results, several significant con-
founders were matched. Age and sex have been shown to
influence progression of high-level hepatic diseases in CHB
patients [12]. A high HBV DNA copy number may inde-
pendently accelerate progression of hepatocirrhosis and
HCC [13, 14]. Additionally, compared with genotype B,
genotype C was related to more aggressive hepatic
Table 1 Main characteristics of included trials
Study NCA NCO Mutation site Detection method Matching factors
Age Sex Genotype HBV DNA
Aiming Zhang, 2013 29 52 T1753V, A1762T, G1764A, A1762T/G1764A,
A1846T, G1896A, G1899A
NP, AS + + + +
Aiming Zhang2, 2013 58 51 T1753V, A1762T, G1764A, A1762T/G1764A,
A1846T, G1896A, G1899A
NP, AS + + + +
Lei Xiao, 2013 77 136 T1753V, A1762T/G1764A, C1766T, T1768A,
A1846T, G1862T, G1896A, G1899A
NP, AS + + - -
Xiaodong Li, 2013 146 239 T1753V, A1762T/G1764A, C1766T, T1768A,
A1846T, G1896A, G1899A
NP, AS + + - -
X Ren, 2010 (40) 75 328 T1753V, A1762T, G1764A, C1766T, T1768A,
G1896A, G1899A
NP, AS + + + +
Zhihui Xu, 2010 298 495 T1753V, A1762T, G1764A, C1766T, T1768A,
G1862T, G1896A, G1899A
NP, AS + + + -
Ling Yang, 2010 39 44 A1762T/G1764A, G1862T, G1896A, G1899A SNP, AS - + + -
Zhengang Zhao, 2010 20 19 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, A1846T, G1862T, G1896A,
G1899A, A1762T/G1764A/G1896A
NP, DS - + + -
Xiaoyan Ma, 2012 44 28 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, A1846T, G1896A, G1899A,
A1762T/G1764A/G1896A
NP, S - + + -
Zhiwei Li, 2002 13 10 A1846T, G1862T, G1896A RP, SA ND ND ND -
Shoubing Tang, 2005 30 30 A1762T/G1764A, G1896A RP, CS + + ND -
Yintang Jia, 2009 8 78 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, A1846T, G1896A, G1899A
NP, DS ND ND ND -
Ling Jiang, 2013 146 239 A1762T/G1764A, G1896A QPMK, DS + + ND -
Wenjun Du, 2005 9 75 A1762T, G1764A, G1896A RP, GC, S ND ND ND -
Xiumei Zhou, 2009 80 80 A1762T/G1764A, G1896A, G1899A RP, GC + + ND -
Mingxian Zhou, 2004 22 56 A1762T, G1896A UK ND ND + -
Xiaoqiang Ren, 2009 348 610 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, G1862T, G1896A, G1899A,
A1762T/G1764A/G1896A
NP, AS + + + -
Lei Jiang, 2010 26 78 G1896A NP, RFLP ND ND ND -
Jinqiang Li, 2006 30 20 A1762T/G1764A, G1896A RP, MS + + ND -
Chengyong Liu, 2007 34 186 A1762T/G1764A, G1896A, A1762T/G1764A/
G1896A
RP, MGS ND ND ND -
Xinyu Liu, 2005 14 75 A1762T, G1764A, A1762T/G1764A, G1896A,
A1762T/G1764A/G1896A
LAS ND ND ND -
Shuren Liang, 2003 23 68 G1896A RP, OAS ND + ND -
Zhidong Zang, 2007 17 81 A1762T/G1764A RP, LAS ND ND ND -
Tao Yan, 2010 49 45 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, A1846T, G1896A, G1899A,
A1762T/G1764A/G1896A
NP, AS - + + -
Wei Guo, 2006 38 40 T1753V, A1762T, G1764A, A1762T/G1764A,
C1766T, T1768A, G1862T, G1896A, G1899A,
A1762T/G1764A/G1896A
RP, CS + + ND -
Yanhong Yu, 2008 25 98 A1762T/G1764A RP, GC ND ND ND -
Guanghui Wu, 2008 30 30 A1762T/G1764A, G1896A RP, RFLP ND + + -
Hangdi Xu, 2013 12 12 A1762T, G1764A, A1846T, G1896A RP, IS + + + +
Fan Li, 2008 (31) 87 196 T1753V, A1762T, G1764A, G1862T, G1896A,
G1899A
NP, AS ND + ND -
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Table 1 Main characteristics of included trials (Continued)
Lu Xu, 2012 64 69 T1753V, A1762T, G1764A, A1762T/G1764A,
T1768A,
G1862T, G1896A, G1899A, A1762T/G1764A/
G1896A
RP, AS + - ND -
Hangdi Xu2, 2013 104 254 A1846T, G1896A SNP, AS ND - - -
NCA number of ACLF patients, NCO number of CHB patients, S sequencing, Apparatus unknown, NP nested PCR, SNP semi-nested PCR, RP routine PCR, AS ABI3730XL PRISM
sequencing, SA Sequence Analysis, CS CEQ2000XL sequencing, DS direct sequencing, QPMK Quickchange point mutation kit, GC gene chip hybrid, UK
unknown, RFLP restriction fragment length polymorphism, MS MegaBACE DNA sequencing, MGS Mgeabace-500 sequencing, LAS LicorIR2 Automatic DNA
sequencing, OAS OpenGene Automated DNA Sequencing, IS Illumina sequencing, ND not determined, + = matched; - = unmatched; ABI PRISM 3730xl
DNA Analyzer
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rhosis and HCC development [15–17], although an associ-
ation between HBV genotypes B and C and ACLF was not
suggested in our study. Most mutations remained signifi-
cantly associated with ACLF development in age and sex-
matched groups and the association with G1896A was still
significant after matching age, sex, HBV genotype and HBV
DNA load. However, the summary ORs were higher in the
confounder-unmatched and age- or sex-only-matched
studies than in the age, sex, genotype and DNA load-
matched studies. Thus, our results suggest a significant as-
sociation between HBV variations in BCP/PC regions and
the risks of developing ACLF.
The causal relationship between HBV BCP/PC muta-
tions and ACLF development remains unknown. ACLF
development was promoted by both acute factors (pre-
cipitating events) and chronic factors (underlying
chronic liver diseases) [18]. Previous studies indicated
that the role of HBV BCP/PC mutations that promote
ACLF were more likely to influence the severity of
chronic factors, because the mutations were detected
both in CHB and HBV-ACLF patients. It was also
reported that HBV BCP/PC variations appeared less fre-
quently in CHB patients than in cirrhotic patients
[19, 20], suggesting a process where mutations accumu-
late during CHB infection and are associated with late-
stage viral infection. Thus, these results suggested that
patients with BCP/PC mutations had more advanced
HBV-related chronic liver diseases, and thus were more
susceptible to hepatic insult and more likely to develop
ACLF. Accumulating evidence suggests that mutations
in the BCP/PC region might exacerbate liver injury by
affecting HBeAg expression and/or viral replication,
which may in turn affect the immune response to HBV
[21]. For example, Yang et al. suggested that HBeAg ex-
pression in the perinatal infection period caused im-
mune tolerance [22]. Another characteristic of HBeAg
that might accelerate chronic infection is that it may
imitate the core protein to weaken the immune response
caused by antibodies in infected hepatocytes [10]. When
the occurrence of HBV mutants in different phenotypes
disturbs the balance, the altered virus–cell relationshipmight activate adverse immune responses in some pa-
tients, causing massive hepatocyte necrosis.
When exploring the potential value of HBV variation in
predicting HBV-ACLF, we found that T1753V, G1764A,
C1766T, T1768A, G1899A and G1896A/A1762T/G1764A
triple mutations were useful in predicting ACLF. A
combination of A1762T/G1764A and G1896A showed
a higher specificity than A1762T/G1764A double muta-
tions (Table 4), suggesting that mutations that accumulate
at different sites have synergistic effects in promoting the
risk of HBV-ACLF. The results indicated that the above
HBV mutations may be used as biomarkers for supporting
the development of HBV-associated ACLF.
Our study also showed the relationship between HBeAg-
negative status and the risk of ACLF using a pooled
OR= 2.813, p < 0.001. However this relationship was prob-
ably not independent. In G1896A patients, the concen-
tration of serum toll-like receptor 2 (TLR2) reached a
significantly higher level than in HBV-infected patients
lacking G1896A [23]. In the absence of HBeAg, HBV
up-regulated TLR2 expression on CD14+ cells [24].
TLR2 is a potential connection between G1896A and
HBeAg-negative status.
This study had several limitations. First, all trials were ob-
servational so that unidentified confounders could not be
eliminated. Second, because we searched only Chinese and
English articles, selection bias based on language could not
be avoided. Third, the data was insufficient to allow analysis
of mutations such as G1896A/G1899A, G1896A/G1899A/
A1762T/G1764A and C1913V that were implicated in
ACLF development in some studies [25–31]. Additionally,
HBV mutations in other regions were not analyzed in the
study. For example, pre-S/S region mutations were ob-
served at an advanced stage of chronic HBV infection
[32, 33]. The pre-S deletion mutation has been reported to
increase with liver disease progression [34]. In addition,
pre-S/S region mutations could alter the immune response
against HBV by affecting neutralization antibody epitopes
[35] or cytotoxic T lymphocyte epitope binding affinity
[36]. Thus, ongoing studies are needed to evaluate the clin-
ical relevance of rare mutations in the BCP region and mu-
tations in other regions. Fourth, the conclusions in this
Table 2 Patient characteristics of included trials
Trials Group N Age, y Gender (m/f) Genotype (B/O) HBeAg (P/N) TB (μmol/L) HBV DNA (log10IU/ml)
Aiming Zhang A 29 43.4 27/2 7/22 11/18 330.2 3.86
C 52 42.3 42/10 16/36 32/20 NG 4.63
Aiming Zhang2 A 58 47.4 48/10 12/46 26/32 338.4 4.02
C 51 46.2 39/12 8/43 19/32 NG 4.69
Lei Xiao A 77 38.2 70/7 71/6 22/55 427.5 NG
C 136 36.9 113/23 82/54 79/57 37.62 NG
Xiaodong Li A 146 47.4 119/27 30/116 45/101 313.4 5
C 239 46.2 207/32 52/187 140/99 74.4 5.8
X Ren A 75 39 67/8 23/52 29/46 451 5.3
C 328 38 281/47 54/274 194/134 12.8 5.2
Zhihui Xu A 298 45.9 255/43 63/235 99/199 418.5 5.48
C-M/S 495 38.3/39.1 427/68 82/413 261/234 16.4/164.2 5.26/5.99
Ling Yang A 39 36 36/3 24/10 11/28 353 5.75
C 44 26 36/8 22/22 36/8 NG 9.16
Zhengang Zhao A 20 49.7 14/6 0/16 8/12 287.37 5.82
C 19 40.37 14/5 2/15 14/5 19.75 7.67
Xiaoyan Ma A 44 51.6 31/13 0/44 NG NG NG
C 28 38.7 20/8 2/26 NG NG NG
Zhiwei Li A 13 21 to 58 17/6 NG NG NG NG
C 10 NG NG NG NG
Shoubing Tang A 30 21 25/5 NG 13/17 NG 1.47
C 30 20 24/6 NG 16/14 NG 3.29
Yintang Jia A 8 NG NG NG NG NG NG
C 78 NG NG NG NG NG NG
Ling Jiang A 146 46 119/27 NG 49/97 313.4 5
C-M/S 239 41/38 206/33 NG 146/93 42.38/106.54 6.27/5.39
Wenjun Du A 9 NG NG NG NG NG NG
C 75 NG NG NG NG NG NG
Xiumei Zhou A 80 48.6 108/72 NG NG NG NG
C 80 NG NG NG NG
Mingxian Zhou A 22 NG NG 3/19 NG NG 4.31
C 56 NG NG 9/47 NG NG 4.72
Xiaoqiang Ren A 348 46 292/56 53/200 132/216 255.9 4.55
C-M/S 610 38/35 518/92 95/476 386/224 12.4/55.4 4.43/5.21
Lei Jiang A 26 NG NG NG NG NG NG
C 78 NG NG NG NG NG NG
Jinqiang Li A 30 48.1 24/6 NG NG NG NG
C 20 43.9 15/5 NG NG NG NG
Chengyong Liu A 34 NG NG NG NG NG NG
C 186 NG NG NG NG NG NG
Xinyu Liu A 14 NG NG NG NG NG NG
C 75 NG NG NG NG NG NG
Shuren Liang A 23 39.71 18/5 NG NG NG NG
C-M0/M1/S 68 35/36.1/35.5 55/13 NG NG NG NG
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Table 2 Patient characteristics of included trials (Continued)
Zhidong Zang A 17 NG 10/7 NG NG 342.3 2.25
C 81 NG 64/17 NG NG 51.9 1.83
Tao Yan A 49 45.8 42/7 9/40 23/26 312.2 4.88
C 45 33.9 36/9 12/33 36/9 16.5 6.91
Wei Guo A 38 32.6 34/4 NG 21/17 NG 5.09
C 40 30.2 33/7 NG 26/14 NG 5.48
Yanhong Yu A 25 NG NG NG NG NG NG
C 98 NG NG NG NG NG NG
Guanghui Wu A 30 40 25/5 6/24 NG NG NG
C 30 29 20/10 4/26 NG NG NG
Hangdi Xu A 12 35 11/1 10/2 4/8 324.9 6.71
C 12 35.7 10/2 8/4 10/2 15.6 6.74
Fan Li A 87 45.4 69/18 NG 27/60 331 4.42
C 196 38.8 170/26 NG 130/66 23.8 5.42
Lu Xu A 64 35.1 57/7 NG 31/33 372.2 3.89
C 69 29.5 48/21 NG 53/16 46.5 5.49
Hangdi Xu2 A 104 40.9 91/13 68/36 51/53 317.5 6.09
C-M/S 254 37.6/40.7 186/68 51/203 185/69 14.9/98.3 6.14/5.77
A ACLF patient group, C CHB patient group, N number of subjects, M0 mild, M1 moderate, S severe, NG not given, m/f male/female, B/O genotype B/other
genotypes, TB Total bilirubin, HBeAg hepatitis B e antigen, P HBeAg positive, N HBeAg negative, PTA Prothrombin activity, ALT alanine aminotransferase, AST
Aspertate Aminotransferase
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selected trials were conducted in China. Although no study
has reported a direct relationship between the risk of ACLF
and country or race, the distribution of HBV genotypes or
quasispecies differs among countries and races. For ex-
ample, the most prevalent HBV genotypes in China are B
and C, whereas genotypes A and D are the most prevalent
in Europe [37]. Although our analysis did not show a differ-
ent association between genotype B or C and ACLF risk, it
is unknown whether there was a different connection be-
tween other HBV genotypes and ACLF. Thus, this conclu-
sion needs to be validated for countries or races where
other HBV genotypes are the most prevalent. Fifth, sum-
mary ORs were not conducted in most manuscripts in-
cluded in this meta-analysis and there were no adjusted
ORs. Sixth, if the sample size were sufficiently large, group-
ing the HBV patients based on grades, such as HBV car-
riers, CHB and hepatocirrhosis, would show whether the
mutations accumulated during CHB progressed to ad-
vanced liver diseases, including ACLF.
We discovered that HBV BCP/PC variations such as
T1753V, A1762T, G1764A, A1762T/G1764A, C1766T,
T1768A, A1846T, G1896A, G1899A and G1896A/
A1762T/G1764A, and HBeAg-negative status corre-
lated with an increased risk of HBV-ACLF. Detecting
these variations in CHB patients may help to identify
those who are at a high risk of developing ACLF. How-
ever, further prospective studies are needed to confirmour findings and whether HBV BCP/PC mutations con-
tribute directly to the development of ACLF. The effect
of HBV BCP/PC mutations on host viral-specific im-
munity also needs to be clarified.
Conclusions
The HBV BCP/PC mutations T1753V, A1762T, G1764A,
C1766T, T1768A, A1846T, G1896A and G1899A, and
an HBeAg-negative status correlate with an increased
risk of HBV-ACLF.
Methods
Search strategy and inclusion/exclusion criteria
We searched PubMed using the following strategy:
(“Hepatitis B virus” [Mesh]) AND “mutation” [Mesh]
from January 1, 1950 to January 31, 2014. The search
strategy for EMbase was “pub-date > 1994 and TITLE-
ABSTR-KEY (hepatitis B virus), and TITLE-ABSTR-
KEY (mutation)”. Biomed Central was searched using
“hepatitis B virus (All words) in Title + Abstract +
Text, and mutation (All words) in Title + Abstract +
Text from 1997 to 2014”. ClinicalTrials was searched
with “hepatitis B virus” AND “mutation” without limi-
tation. The main Chinese databases were searched
using: Chinese Biological Medicine (1978 to January
31, 2014), WANFANG DATA (1997 to January 31,
2014), VIP (1989 to January 31, 2014), China National
Knowledge Infrastructure (1994 to January 31, 2014);
Fig. 2 Summary odds ratio (OR) of acute-on-chronic liver failure for A1762T, G1764A, A1762T/G1764A and G1896A mutations. Squares represent
study-specific estimates (size of the square reflects the study-specific statistical weight); horizontal lines represent 95 % confidence intervals (CIs);
diamonds represent summary estimates with corresponding 95 % CIs. Test for heterogeneity: (G1896A) p = 0.002, I2 = 48.1 %; (A1762T/G1764A)
p < 0.001, I2 = 80.7 %; (A1762T) p = 0.164, I2 = 25.7 %; (G1764A) p = 0.004, I2 = 56.4 %. A random-effects model was used for G1896A, A1762T/
G1764A and G1764A, and a fixed-effects model was used for A1762T. All statistical tests were two-sided
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“mutation” [Abstract]. The inclusion criteria were: 1)
studies contained control groups; 2) ACLF diagnosis
was based on the APASL criteria, as follows: serum
bilirubin ≥5 mg/dl and coagulopathy (INR ≥ 1.5 or
PTA < 40 %) are mandatory. Ascites and/or encephal-
opathy were determined by physical examination
within 4 weeks [38], or the ACLF diagnosis was based
on the criteria recommended by the Chinese Society
of Infectious Disease and the Chinese Society of Hepatol-
ogy: HBV infection history; total serum bilirubin >10 mg/
dl, PTA < 40 % and recent complications that also meet
APASL criteria; 3) BCP or PC mutations were detected; 4)
the outcome was ACLF; and 5) ORs and 95 % CIs were
shown or could be calculated from original data. Studies
without control groups or studies in which patients were
co-infected with another hepatitis virus or HIV, with the
presence of other underlying chronic liver diseases (such asWilson disease and autoimmune hepatitis) or liver cancer
were excluded. For studies that contained over-lapping
populations, the study containing the larger number of par-
ticipants or the most recent study was included.
Data extraction
Feishu Hu and Sheng Bi extracted information inde-
pendently as follows: publication year, location, study
design, number and subject characteristics, HBV mu-
tations, genotypes, HBeAg status, variation testing ap-
proach and probable confounding factors. All authors
discussed results and reached an agreement if there
were discrepancies. BCP/PC region mutation sites
were included. Patients co-infected with wild-type vi-
ruses and BCP/PC mutated viruses were excluded.
Subjects with a single mutation were excluded when
assessing A1762T/G1764A double mutations and
A1762T/G1764A/G1896A triple mutations.
Table 3 Pooled unadjusted risk estimates of ACLF after stratification or matching
Mutation site Matching factor OR _LCI _UCI P
T1753V unmatched 1.919 1.414 2.606 0.000
age and sex matched 1.481 0.982 2.234 0.061
age, sex, genotype and HBV DNA matched ND ND ND ND
A1762T unmatched 2.685 2.264 3.185 0.000
age and sex matched 2.307 1.555 3.422 0.000
age, sex, genotype and HBV DNA matched 1.326 0.585 3.007 0.499
G1764A unmatched 2.901 2.041 4.122 0.000
age and sex matched 2.023 1.013 4.041 0.046
age, sex, genotype and HBV DNA matched 1.310 0.555 3.094 0.538
A1762T/G1764A unmatched 2.376 1.548 3.648 0.000
age and sex matched 2.602 1.270 5.333 0.009
age, sex, genotype and HBV DNA matched ND ND ND ND
G1896A unmatched 2.181 1.800 2.642 0.000
age and sex matched 2.014 1.505 2.695 0.000
age, sex, genotype and HBV DNA matched 1.479 1.017 2.152 0.041
G1899A unmatched 3.525 2.882 4.312 0.000
age and sex matched 3.171 2.464 4.081 0.000
age, sex, genotype and HBV DNA matched ND ND ND ND
C1766T unmatched 1.849 1.403 2.437 0.000
age and sex matched 1.719 1.226 2.411 0.002
age, sex, genotype and HBV DNA matched ND ND ND ND
T1768A unmatched 2.199 1.563 3.094 0.000
age and sex matched 2.203 1.425 3.405 0.000
age, sex, genotype and HBV DNA matched ND ND ND ND
A1846T unmatched 3.163 2.157 4.639 0.000
age and sex matched 2.854 2.127 3.831 0.000
age, sex, genotype and HBV DNA matched ND ND ND ND
ND not determined, OR odds ratio, _LCI low limit of 95 % confidence interval, _UCI upper limit of 95 % confidence interval
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Feishu Hu and Sheng Bi independently evaluated the
quality of trials using the NOS, which was developed for
case–control studies. Each study that was included was
judged on three broad perspectives: selection of study
groups, comparability of groups and ascertainment of
exposure for case–control studies. Disagreements were
resolved by discussion between all authors.
Statistical analysis
The effect measures were ORs and the corresponding
95 % CIs. Within-study heterogeneity was assessed using
Cochrane’s Q-test and the I2 test [39]. Summary ORs
were pooled by a random or fixed-effect model based on
the results of a heterogeneity test. To detect the stability
with primary analysis, we conducted a sensitivity analysis
using a “leave one out analysis”. Publication bias was de-
tected using funnel plots and the Egger test [40].Significant publication bias was believed to be present if
a p value was less than 0.1. We also conducted subgroup
analysis by stratifying the study participants according to
probable confounders such as sex, age, HBV DNA and
HBV genotype and we calculated the respective sum-
mary risk estimates. We used Stata software (version
12.0; Stata Corp, College Station, TX) to conduct the
analysis and to calculate the ACLF summary estimates
for the HBV genotype, HBeAg status and T1753V,
A1762T, G1764A, A1762T/G1764A, C1766T, T1768A,
A1846T, G1862T, G1896A, G1899A and A1762T/
G1764A/G1896A mutations for ACLF patients. The fol-
lowing mutation sites were also detected in the included
studies: G1613A, C1653T, 1752G, T1754V, T1753V/
A1762T/G1764A, T1758C, G1764A/C1766T/T1768A,
T1770A, 1773 T, G1775A, C1799V, T1800C, T1803C,
G1809T, A1814C, A1837G, A1846G, T1853C, T1858C,
G1896A/G1899A, G1896A/G1899A/A1762T/G1764A,












T1753V pos 392 397 29.3 (26.9 to 31.9) 83.3 (81.8 to 84.8) 49.7 (46.1 to 53.2) 67.8 (66.0 to 69.5)
neg 945 1986
A1762T pos 872 1207 74.5 (71.9 to 76.9) 45.8 (43.7 to 47.9) 41.9 (39.8 to 44.1) 77.3 (75.0 to 80.0)
neg 299 1019
G1764A pos 921 228 43.0 (40.9 to 45.1) 80.6 (78.3 to 82.9) 80.1 (77.7 to 82.4) 43.7 (41.6 to 45.9)
neg 1221 949
A1762T/G1764A pos 678 825 51.6 (48.9 to 54.4) 63.1 (61.1 to 65.1) 45.1 (42.6 to 47.7) 69.0 (66.9 to 71.0)
neg 635 1412
C1766T pos 113 118 10.3 (8.6 to 12.2) 94.1 (93.0 to 95.1) 48.9 (42.3 to 55.6) 65.8 (64.0 to 67.5)
neg 986 1897
T1768A pos 80 64 6.9 (5.5 to 8.5) 96.9 (96.1 to 97.6) 55.6 (47.1 to 63.8) 65.1 (63.4 to 66.8)
neg 1083 2020
A1846T pos 304 251 54.7 (50.4 to 58.9) 72.8 (69.8 to 75.6) 54.8 (50.5 to 59.0) 72.7 (69.7 to 75.5)
neg 252 670
G1896A pos 1025 1254 52.6 (50.4 to 54.8) 65.6 (64.0 to 67.1) 45.0 (42.9 to 47.0) 72.1 (70.5 to 73.6)
neg 924 2386




pos 107 135 17.6 (14.7 to 20.9) 87.4 (85.2 to 89.3) 44.2 (37.9 to 50.7) 65.1 (62.6 to 67.6)
neg 500 934
Pos mutation positive, neg mutation negative, PPV positive predictive value, NPV negative predictive value
Fig. 3 Summary OR of acute-on-chronic liver failure for genotypes and HBeAg status. Summary OR for genotypes B and C and for HBeAg-negative to
HBeAg-positive status. Squares represent study-specific estimates (the size of the square reflects the study-specific statistical weight); horizontal
lines represent 95 % CIs; diamonds represent summary estimates with corresponding 95 % CIs. Test for heterogeneity: p < 0.001, I2 = 79.0 %. A
random-effects model was used. All statistical tests were two-sided
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Table 5 Assessment of within-group heterogeneity, publication bias and sensitivity analysis
Mutation site P value for heterogeneity P value for Egger’s test Sensitivity analysis
T1753V 0.006 0.923 -
A1762T 0.164 0.181 -
G1764A 0.004 0.100 -
A1762T/G1764A 0.000 0.455 -
C1766T 0.852 0.300 -
T1768A 0.681 0.291 -
A1846T 0.037 0.856 -
G1862T 0.001 0.125 +
G1896A 0.002 0.520 -
G1899A 0.307 0.591 -
G1896A/A1762T/G1764A 0.073 0.045 -
The summary OR did not change statistical significance when running sensitivity analysis. ‘+’ = the P value for summary OR reached statistical significance of 0.001 when the
trial conducted by Xiaoqiang Ren was removed
Fig. 4 Funnel plot for A1762T, G1764A, A1762T/G1764A and G1896A. The dashed line represents 95 % CIs. Circles represent individual studies
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Hu et al. Virology Journal  (2015) 12:87 Page 12 of 13C1913V, 1915A/C, T1938C, A1979G, T1961V and
T1753V/A1762T/G1764A/G1896A/G1899A, but they
were not included in this meta-analysis because the data
was insufficient. Variation frequency between CHB pa-
tients and HBV-ACLF patients was compared using the
Chi-squared test. Sensitivity and specificity of HBV mu-
tations for ACLF was evaluated to indicate the possibility
of using certain mutations to predict the development of
HBV-ACLF.
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